<?xml version="1.0" encoding="UTF-8"?>
<!--Generated by Squarespace Site Server v5.11.81 (http://www.squarespace.com/) on Tue, 29 May 2012 15:41:54 GMT--><feed xmlns="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/"><title>Healthcare News</title><subtitle>Healthcare News</subtitle><id>http://www.freshapple.com/healthcare-news/</id><link rel="alternate" type="application/xhtml+xml" href="http://www.freshapple.com/healthcare-news/"/><link rel="self" type="application/atom+xml" href="http://www.freshapple.com/healthcare-news/atom.xml"/><updated>2011-09-05T01:26:51Z</updated><generator uri="http://www.squarespace.com/" version="Squarespace Site Server v5.11.81 (http://www.squarespace.com/)">Squarespace</generator><entry><title>Google is Fined for Placing Banned Pharma Ads</title><category term="Medical News"/><category term="google"/><category term="online advertising"/><category term="pharma ads"/><id>http://www.freshapple.com/healthcare-news/2011/8/24/google-is-fined-for-placing-banned-pharma-ads.html</id><link rel="alternate" type="text/html" href="http://www.freshapple.com/healthcare-news/2011/8/24/google-is-fined-for-placing-banned-pharma-ads.html"/><author><name>[Your Name Here]</name></author><published>2011-08-24T16:06:09Z</published><updated>2011-08-24T16:06:09Z</updated><content type="html" xml:lang="en-US"><![CDATA[<p>"Google Inc will pay $500 million to settle government charges that it showed ads for pharmacies that operate illegally, regulators are expected to announce on Wednesday, according to a report in the New York Times." To read the entire article click <a class="offsite-link-inline" title="http://www.reuters.com/article/2011/08/24/us-google-idUSTRE77N4A220110824" href="http://www.reuters.com/article/2011/08/24/us-google-idUSTRE77N4A220110824" target="_blank">here.</a></p>]]></content></entry><entry><title>Clinical trials going global...</title><category term="Medical News"/><category term="clinical research"/><category term="clinical trials"/><id>http://www.freshapple.com/healthcare-news/2011/5/6/clinical-trials-going-global.html</id><link rel="alternate" type="text/html" href="http://www.freshapple.com/healthcare-news/2011/5/6/clinical-trials-going-global.html"/><author><name>[Your Name Here]</name></author><published>2011-05-06T11:55:10Z</published><updated>2011-05-06T11:55:10Z</updated><content type="html" xml:lang="en-US"><![CDATA[<p>"...<span id="articleText">Today, the clinical trials business has gone  global as drugmakers seek cheaper venues for studies and cast their net  further afield for big pools of "treatment-naive" patients who are not  already taking other drugs that could make them unsuitable subjects for  testing new ones. And it is not only the practicalities of running big  clinical trials as efficiently and cheaply as possible that is driving  the change." To read the entire Reuters article, written by Ben Hirschler, click <a class="offsite-link-inline" title="http://www.reuters.com/article/2011/05/06/us-pharmaceuticals-trials-idUSTRE7450SV20110506" href="http://www.reuters.com/article/2011/05/06/us-pharmaceuticals-trials-idUSTRE7450SV20110506" target="_blank">here</a>.</span></p>]]></content></entry><entry><title>Medtech companies post strong results, raise views</title><category term="Earnings reports"/><category term="Newspaper"/><id>http://www.freshapple.com/healthcare-news/2011/4/21/medtech-companies-post-strong-results-raise-views.html</id><link rel="alternate" type="text/html" href="http://www.freshapple.com/healthcare-news/2011/4/21/medtech-companies-post-strong-results-raise-views.html"/><author><name>[Your Name Here]</name></author><published>2011-04-21T14:45:06Z</published><updated>2011-04-21T14:45:06Z</updated><content type="html" xml:lang="en-US"><![CDATA[<p>"Medical products makers Baxter International Inc (<span id="symbol_BAX.N_0"><a href="http://www.reuters.com/finance/stocks/overview?symbol=BAX.N">BAX.N</a></span>) and Covidien Plc (<span id="symbol_COV.N_1"><a href="http://www.reuters.com/finance/stocks/overview?symbol=COV.N">COV.N</a></span>) posted stronger-than-expected quarterly results, boosted by robust demand, and they raised their full-year outlooks.</p>
<p>Shares of both companies were up about 3 percent in trading before the market opened."&nbsp; To read the entire Reuters article, click <a class="offsite-link-inline" title="http://www.reuters.com/article/2011/04/21/medtech-idUSN2125291520110421" href="http://www.reuters.com/article/2011/04/21/medtech-idUSN2125291520110421" target="_blank">here</a>.</p>]]></content></entry><entry><title>A story to put you a slumber...</title><category term="Medical News"/><category term="Sleep Apnea"/><category term="new treatment"/><id>http://www.freshapple.com/healthcare-news/2011/4/19/a-story-to-put-you-a-slumber.html</id><link rel="alternate" type="text/html" href="http://www.freshapple.com/healthcare-news/2011/4/19/a-story-to-put-you-a-slumber.html"/><author><name>[Your Name Here]</name></author><published>2011-04-19T12:06:01Z</published><updated>2011-04-19T12:06:01Z</updated><content type="html" xml:lang="en-US"><![CDATA[<p>"Snoring and waking up at night are common nighttime annoyances, but  for many, they are signs of a major health problem: sleep apnea. A  number of companies are marketing nasal devices to treat the disorder.  Scientists say the nonprescription devices haven't been adequately  studied, but two new studies found a prescription device effective in  some patients.</p>
<p>Obstructive sleep apnea is a disorder in which a person stops  breathing when the airway closes. Common reasons are blockages to the  airway, either by tissue in the back of the throat collapsing or the  tongue falling back into the throat. An effective treatment involves  using a continuous positive airway pressure, or CPAP, machine, which  forces air into the throat to keep it open. " &nbsp;To read the entire Wall Street Article, written by Laura Johannes, click <a class="offsite-link-inline" title="http://online.wsj.com/article/SB10001424052748704004004576270972075338848.html" href="http://online.wsj.com/article/SB10001424052748704004004576270972075338848.html" target="_blank">here</a>.</p>]]></content></entry><entry><title>Making Clinical Trials Less of a Tribulation</title><category term="Medical News"/><category term="clinical research"/><category term="clinical trials"/><id>http://www.freshapple.com/healthcare-news/2011/3/27/making-clinical-trials-less-of-a-tribulation.html</id><link rel="alternate" type="text/html" href="http://www.freshapple.com/healthcare-news/2011/3/27/making-clinical-trials-less-of-a-tribulation.html"/><author><name>[Your Name Here]</name></author><published>2011-03-28T02:11:40Z</published><updated>2011-03-28T02:11:40Z</updated><content type="html" xml:lang="en-US"><![CDATA[<p>"For developers of new drugs and treatments, one of the toughest hurdles  has nothing to do with medicine. It's recruiting patients for clinical  trials. And when it comes to recruiting minority patients, the challenge  is even greater.</p>
<p>New approaches are being tried that can dramatically speed up the  recruiting process and reach more patients from groups frequently  underrepresented in studies.</p>
<p>At the heart of these new methods is the shift to electronic medical  records, which makes patient searches faster and more methodical&mdash;in part  by also allowing researchers to involve patients in trials from day one  of their treatment." To read the entire WSJ article, written by Jennifer Corbett Dooren, click <a class="offsite-link-inline" title="http://online.wsj.com/article_email/SB10001424052748703580004576180811400890264-lMyQjAxMTAxMDIwNzEyNDcyWj.html" href="http://online.wsj.com/article_email/SB10001424052748703580004576180811400890264-lMyQjAxMTAxMDIwNzEyNDcyWj.html" target="_blank">here.</a></p>]]></content></entry><entry><title>Patent Woes Threaten Drug Firms (and healthcare marketing budgets?)</title><category term="Newspaper"/><category term="big pharma"/><category term="healthcare marketing"/><id>http://www.freshapple.com/healthcare-news/2011/3/7/patent-woes-threaten-drug-firms-and-healthcare-marketing-bud.html</id><link rel="alternate" type="text/html" href="http://www.freshapple.com/healthcare-news/2011/3/7/patent-woes-threaten-drug-firms-and-healthcare-marketing-bud.html"/><author><name>[Your Name Here]</name></author><published>2011-03-07T16:14:10Z</published><updated>2011-03-07T16:14:10Z</updated><content type="html" xml:lang="en-US"><![CDATA[<p>"At the end of November, <a class="meta-org" title="More information about Pfizer Inc" href="http://topics.nytimes.com/top/news/business/companies/pfizer_inc/index.html?inline=nyt-org">Pfizer</a> stands to lose a $10-billion-a-year revenue stream when the patent on its blockbuster <a class="meta-classifier" title="In-depth reference and news articles about Cholesterol." href="http://health.nytimes.com/health/guides/nutrition/cholesterol/overview.html?inline=nyt-classifier">cholesterol</a> drug <a class="meta-classifier" title="Recent and archival health news about Lipitor." href="http://topics.nytimes.com/top/news/health/diseasesconditionsandhealthtopics/lipitor_drug/index.html?inline=nyt-classifier">Lipitor</a> expires and cheaper generics begin to cut into the company&rsquo;s huge sales.</p>
<p>The loss poses a daunting challenge for Pfizer, one shared by nearly  every major pharmaceutical company. This year alone, because of patent  expirations, the drug industry will lose control over more than 10  megamedicines whose combined annual sales have neared $50 billion."&nbsp;</p>
<p>To read the entire New York Times article written by Duff Wilson, click <a class="offsite-link-inline" title="http://www.nytimes.com/2011/03/07/business/07drug.html?_r=2&amp;ref=todayspaper" href="http://www.nytimes.com/2011/03/07/business/07drug.html?_r=2&amp;ref=todayspaper" target="_blank">here</a>.</p>]]></content></entry><entry><title>Putting the lid on the pot: Judge issues injunction against L.A.'s medical marijuana law</title><category term="Medical News"/><category term="drug prescrptions"/><category term="illegal drugs"/><category term="medical marijuana"/><id>http://www.freshapple.com/healthcare-news/2010/12/11/putting-the-lid-on-the-pot-judge-issues-injunction-against-l.html</id><link rel="alternate" type="text/html" href="http://www.freshapple.com/healthcare-news/2010/12/11/putting-the-lid-on-the-pot-judge-issues-injunction-against-l.html"/><author><name>[Your Name Here]</name></author><published>2010-12-11T15:10:04Z</published><updated>2010-12-11T15:10:04Z</updated><content type="html" xml:lang="en-US"><![CDATA[<p>"A judge handed Los Angeles a setback in its faltering drive to limit the number of&nbsp;<a id="HETHT000012" class="taxInlineTagLink" title="Medical Marijuana Therapy" href="http://www.latimes.com/topic/health/health-treatments/medical-marijuana-therapy-HETHT000012.topic">medical marijuana</a>&nbsp;dispensaries, granting a preliminary injunction on Friday that bars the city from enforcing key provisions in its controversial six-month-old ordinance. &nbsp;</p>
<p>The decision, issued by Los Angeles County Superior Court Judge Anthony J. Mohr, leaves the city with limited power to control pot stores, which opened by the hundreds, angering neighborhood activists when city officials failed to enforce a 2007 moratorium.<br /><br />Near the end of his 40-page ruling, Mohr acknowledged "there is a good chance that a large number of collectives could open once this injunction takes effect," but said his order was warranted because the dispensaries that sued the city are highly likely to prevail in a trial." &nbsp;To read the entire LA times article, click <a class="offsite-link-inline" title="http://www.latimes.com/news/local/la-me-1211-marijuana-dispensaries-20101211,0,7140011.story" href="http://www.latimes.com/news/local/la-me-1211-marijuana-dispensaries-20101211,0,7140011.story" target="_blank">here</a>.<br /><br /></p>]]></content></entry><entry><title>Diabetes to double or triple in U.S. by 2050...</title><category term="Medical News"/><category term="clinical research"/><category term="diabetes"/><id>http://www.freshapple.com/healthcare-news/2010/10/24/diabetes-to-double-or-triple-in-us-by-2050.html</id><link rel="alternate" type="text/html" href="http://www.freshapple.com/healthcare-news/2010/10/24/diabetes-to-double-or-triple-in-us-by-2050.html"/><author><name>[Your Name Here]</name></author><published>2010-10-24T15:15:25Z</published><updated>2010-10-24T15:15:25Z</updated><content type="html" xml:lang="en-US"><![CDATA[<p><span class="focusParagraph">
<p>"Up to a third of U.S. adults could have diabetes by 2050 if Americans continue to gain weight and avoid exercise, the Centers for Disease Control and Prevention projected on Friday.</p>
</span></p>
<p>The numbers are certain to go up as the population gets older, but they will accelerate even more unless Americans change their behavior, the CDC said.</p>
<p>"We project that, over the next 40 years, the prevalence of total diabetes (diagnosed and undiagnosed) in the United States will increase from its current level of about one in 10 adults to between one in five and one in three adults in 2050," the CDC's James Boyle and colleagues wrote in their report.</p>
<p>"These are alarming numbers that show how critical it is to change the course of type-2 diabetes," CDC diabetes expert Ann Albright said in a statement.</p>
<p>"Successful programs to improve lifestyle choices on healthy eating and physical activity must be made more widely available because the stakes are too high and the personal toll too devastating to fail."</p>
<p>The CDC says about 24 million U.S. adults have diabetes now, most of them type-2 diabetes linked strongly with poor diet and lack of exercise." To read the entire Reuters article, click <a class="offsite-link-inline" title="http://www.reuters.com/article/idUSTRE69L21Y20101022" href="http://www.reuters.com/article/idUSTRE69L21Y20101022" target="_blank">here</a>.</p>]]></content></entry><entry><title>FDA Funds Pediatric Trial Testing Genetically Reprogrammed HSV to Treat Cancer...</title><category term="Press Releases"/><category term="clinical research"/><id>http://www.freshapple.com/healthcare-news/2010/10/13/fda-funds-pediatric-trial-testing-genetically-reprogrammed-h.html</id><link rel="alternate" type="text/html" href="http://www.freshapple.com/healthcare-news/2010/10/13/fda-funds-pediatric-trial-testing-genetically-reprogrammed-h.html"/><author><name>[Your Name Here]</name></author><published>2010-10-13T17:30:12Z</published><updated>2010-10-13T17:30:12Z</updated><content type="html" xml:lang="en-US"><![CDATA[<p>"A clinical trial testing a genetically reprogrammed herpes simplex virus as treatment for deadly forms of childhood cancer has received a U.S. Food and Drug Administration grant to support the research.</p>
<p>The Phase I trial at Cincinnati Children's Hospital Medical Center currently focuses on testing the safety of the agent HSV1716 in patients. The study includes young patients with solid tumors such as rhabdomyosarcoma or Ewing's sarcoma. These cancers have limited treatment options and survival rates under 30 percent when the cancers recur and spread to other parts of the body." &nbsp;To read the entire press release, click <a class="offsite-link-inline" title="http://www.kansascity.com/2010/10/12/2305228/fda-funds-pediatric-trial-testing.html" href="http://www.kansascity.com/2010/10/12/2305228/fda-funds-pediatric-trial-testing.html" target="_blank">here</a>.</p>]]></content></entry><entry><title>Children remain underrepresented in clinical trials...</title><category term="clinical research"/><category term="clinical trials"/><id>http://www.freshapple.com/healthcare-news/2010/10/6/children-remain-underrepresented-in-clinical-trials.html</id><link rel="alternate" type="text/html" href="http://www.freshapple.com/healthcare-news/2010/10/6/children-remain-underrepresented-in-clinical-trials.html"/><author><name>[Your Name Here]</name></author><published>2010-10-06T18:21:22Z</published><updated>2010-10-06T18:21:22Z</updated><content type="html" xml:lang="en-US"><![CDATA[<p>"To receive medical care that is tailored to their unique needs, children&rsquo;s participation in clinical trials is essential, according to a speaker here at the 2010 American Academy of Pediatrics National Conference and Exhibition.</p>
<p><strong>Gail Pearson, MD,</strong>&nbsp;of the Children&rsquo;s National Medical Center in Washington, D.C., said that research in the pediatric population is needed because this group of patients has special needs that require more than just &ldquo;hand-me-down&rdquo; information derived from studies conducted in adults." &nbsp;To read the complete Pediatric article, click <a class="offsite-link-inline" title="http://www.pediatricsupersite.com/view.aspx?rid=76050" href="http://www.pediatricsupersite.com/view.aspx?rid=76050" target="_blank">here</a>.</p>]]></content></entry></feed>
